Pyelonephritis Drug Pipeline Analysis Report 2025

Pyelonephritis is a bacterial infection of the kidneys that can lead to serious complications if left untreated. The annual prevalence in the United States is approximately 15 to 17 cases per 10,000 females and 3 to 4 cases per 10,000 males. There is a significant unmet clinical need for improved therapies, as current treatment options, mainly antibiotics, face challenges such as drug resistance and suboptimal efficacy in severe cases. The growing focus on innovative drug development, including targeted therapies and advanced diagnostics, is expected to support pipeline growth. These advancements aim to enhance treatment outcomes and address the limitations of current therapeutic options.

Report Coverage

The Pyelonephritis Drug Pipeline Insight Report by the publisher gives comprehensive insights into pyelonephritis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for pyelonephritis. The pyelonephritis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The pyelonephritis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with pyelonephritis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to pyelonephritis.

Pyelonephritis Drug Pipeline Outlook

Pyelonephritis is a kidney infection primarily caused by bacteria ascending from the urinary tract. It occurs when bacteria, commonly Escherichia coli, enter the kidneys, leading to inflammation and possible scarring. The disease can be acute or chronic and is more common in women. The drug pipeline is focused on novel antibiotics, immunotherapies, and vaccines to address antibiotic resistance and improve treatment outcomes.

Pyelonephritis treatment generally involves antibiotics to combat the bacterial infection. In severe cases, intravenous antibiotics or hospitalization may be required. For recurrent infections, long-term antibiotic prophylaxis may be prescribed. Future treatments in the pipeline include targeted therapies and vaccines aimed at preventing infections and reducing antibiotic resistance.

Pyelonephritis Epidemiology

The pyelonephritis drug pipeline targets infections primarily caused by bacteria that ascend from the bladder. Epidemiological data indicates that the prevalence in the United States is 15 to 17 cases per 10,000 females and 3 to 4 per 10,000 males, with an increasing incidence in men over 55 years. In Japan, urinary tract infection hospitalizations occur at 6.8 per 10,000 men and 12.4 per 10,000 women. Pyelonephritis often develops from untreated or severe urinary tract infections.

Pyelonephritis - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of pyelonephritis drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Gene Therapy
• Biologics
• Peptides

By Route of Administration

• Oral
• Parenteral
• Others

Pyelonephritis - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total pyelonephritis clinical trials.

Pyelonephritis - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the pyelonephritis pipeline analysis include small molecules, gene therapy, biologics, and peptides. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for pyelonephritis.

Pyelonephritis Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the pyelonephritis report insights includes the profile of key companies involved in clinical trials and their drugs under development. Below is a list of a few players involved in pyelonephritis clinical trials:

• GlaxoSmithKline
• Medpace, Inc.
• NeuroRx, Inc.
• Spero Therapeutics
• Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
• Evopoint Biosciences Inc.
• Jiangsu HengRui Medicine Co., Ltd.

Pyelonephritis Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for pyelonephritis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of pyelonephritis drug candidates.

Drug: TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion, Dummy Tablets

Sponsored by Spero Therapeutics, the Phase 3 PIVOT-PO study aims to assess the efficacy of oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) compared to intravenous Imipenem-cilastatin in participants with complicated urinary tract infections (cUTI) or acute pyelonephritis (AP). The study, with an estimated 2,648 participants, is expected to be completed by November 2025. The primary objective is to evaluate the overall response at the Test-of-Cure (TOC) visit.

Drug: Meropenem-Vaborbactam, Antibiotics

A Phase 2 study sponsored by Rempex, a subsidiary of Melinta Therapeutics, evaluates the safety, tolerability, and pharmacokinetics of Meropenem-Vaborbactam in children with complicated urinary tract infections, including acute pyelonephritis. The study, expected to be completed by July 2027, aims to enroll 66 participants. The primary objective is to assess the drug's safety and tolerability in this population.

Reasons To Buy This Report

The Pyelonephritis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for pyelonephritis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within pyelonephritis pipeline insights.

Key Questions Answered in the Pyelonephritis - Pipeline Insight Report

• What is the current landscape of pyelonephritis pipeline drugs?
• Which companies/institutions are developing pyelonephritis emerging drugs?
• How many phase II drugs are currently present in pyelonephritis pipeline drugs?
• Which company is leading the pyelonephritis pipeline development activities?
• What is the current pyelonephritis therapeutic assessment?
• What are the opportunities and challenges present in the pyelonephritis drug pipeline landscape?
• What is the efficacy and safety profile of pyelonephritis pipeline drugs?
• Which companies/institutions are involved in pyelonephritis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in pyelonephritis?

This product will be delivered within 3-5 business days.